Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Wyles

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
Development of herpes simplex virus disease in patients who are receiving cidofovirDavid L Wyles, Amita Patel, Nancy Madinger, et al.
Open Forum Infectious Diseases|April 3, 2023
Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)David L Wyles, Minhee Kang, Roy M Matining, et al.
Open Forum Infectious Diseases|July 7, 2018
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)David L Wyles, Minhee Kang, Roy M Matining, et al.
Open Forum Infectious Diseases|December 20, 2021
Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)David L Wyles, Minhee Kang, Roy M Matining, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2009
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivoJohn D Morrey, Brent E Korba, James R Beadle, et al.
Nature Chemical Biology|September 22, 2009
Conformational inhibition of the hepatitis C virus internal ribosome entry site RNAJerod Parsons, M Paola Castaldi, Sanjay Dutta, et al.
Antiviral Research|June 10, 2014
Update on hepatitis C virus resistance to direct-acting antiviral agentsEva Poveda, David L Wyles, Alvaro Mena, et al.
Hepatology (Baltimore, Md.)|December 3, 2021
ReplyAndrew I Aronsohn, Debika Bhattacharya, Timothy R Morgan, et al.
The Journal of Infectious Diseases|January 27, 2012
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antiviralsHaihong Zhu, Flossie Wong-Staal, Haekyung Lee, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2009
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A repliconsDavid L Wyles, Kelly A Kaihara, Brent E Korba, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
Development of herpes simplex virus disease in patients who are receiving cidofovirDavid L Wyles, Amita Patel, Nancy Madinger, et al.
Open Forum Infectious Diseases|April 3, 2023
Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)David L Wyles, Minhee Kang, Roy M Matining, et al.
Open Forum Infectious Diseases|July 7, 2018
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)David L Wyles, Minhee Kang, Roy M Matining, et al.
Open Forum Infectious Diseases|December 20, 2021
Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)David L Wyles, Minhee Kang, Roy M Matining, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2009
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivoJohn D Morrey, Brent E Korba, James R Beadle, et al.
Nature Chemical Biology|September 22, 2009
Conformational inhibition of the hepatitis C virus internal ribosome entry site RNAJerod Parsons, M Paola Castaldi, Sanjay Dutta, et al.
Antiviral Research|June 10, 2014
Update on hepatitis C virus resistance to direct-acting antiviral agentsEva Poveda, David L Wyles, Alvaro Mena, et al.
Hepatology (Baltimore, Md.)|December 3, 2021
ReplyAndrew I Aronsohn, Debika Bhattacharya, Timothy R Morgan, et al.
The Journal of Infectious Diseases|January 27, 2012
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antiviralsHaihong Zhu, Flossie Wong-Staal, Haekyung Lee, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2009
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A repliconsDavid L Wyles, Kelly A Kaihara, Brent E Korba, et al.
Pageof 8